The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

A STING in the long tail?

What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?

August 2, 2019

New developments in Sarcoma

A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche

July 23, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019

How F-star are optimising bispecific antibodies for cancer treatment

Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?

July 10, 2019

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019

Dracarys! How T cell therapy is like Game of Thrones

Is T cell therapy like Game of Thrones?

July 1, 2019

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019

What’s new with Corvus Pharma?

New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...

June 11, 2019

How understanding patient tumours can help us with future IO trials

Looking under the hood to find biomarkers of response and outcomes, ,

June 10, 2019

Did the SOPHIA data set the house on fire?

Thoughts on Macrogenics phase 3 SOPHIA trial exploring margetuximab vs. trastuzumab - hit or miss?

June 4, 2019

Manic Monday at ASCO19!

On KRAS in lung cancer, HRD in pancreatic cancer (not POLO) and genomics in RCC

June 4, 2019

Highlights from Plenary Sunday at ASCO19

A look at some of the hidden gems and struggling compounds in competitive niches at ASCO19

June 3, 2019

Highlights of Day 2 at ASCO19

Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.

June 2, 2019

Highlights of Day 1 of ASCO19

A review of some this key data presented including new compounds in early development and how they stack up against existing therapies.

June 1, 2019

Ten Underrated ASCO19 abstracts

Hidden gems - what to watch out for at ASCO19 off the beaten track amongst the wealth of data to peruse

May 30, 2019

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019

Where’s the next exciting IO target coming from?

Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...

May 20, 2019

Challenges of targeting KRAS G12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019

Can Silverback increase the Firepower of TLR agonists?

A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche

May 9, 2019

Targeting the adenosine pathway in cancer immunotherapy

A look a the updated adenosine pathway landscape and how it is progressing

April 18, 2019